Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma

BACKGROUND: The survival rate for patients with glioblastoma (GBM) remains dismal. New therapies targeting molecular pathways dysregulated in GBM are needed. One such clinical-stage drug candidate, CBL0137, is a curaxin, small molecules which simultaneously downregulate nuclear factor-kappaB (NF-ĸB)...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuro Oncol
Hauptverfasser: Barone, Tara A, Burkhart, Catherine A, Safina, Alfiya, Haderski, Gary, Gurova, Katerina V, Purmal, Andrei A, Gudkov, Andrei V, Plunkett, Robert J
Format: Artigo
Sprache:Inglês
Veröffentlicht: Oxford University Press 2017
Schlagworte:
Basic and Translational Investigation
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5604960/
https://ncbi.nlm.nih.gov/pubmed/27370399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now141
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge